A Prospective 12-Week Study of Quetiapine in Adolescents with Schizophrenia Spectrum Disorders

Schimmelmann, Benno G.; Mehler-Wex, Claudia; Lambert, Martin; Schulze-zur-Wiesch, Constanze; Koch, Eginhard; Flechtner, H.; Gierow, Baerbel; Maier, Joachim; Meyer, Eberhard; Schulte‐Markwort, Michael

doi:10.1089/cap.2007.0048

Cited by 36 publications

(46 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are consistent with previous results from much smaller European samples in which SGA-related weight gain was observed in mainly Caucasian adolescents with bipolar and psychotic disorders (Schimmelmann et al 2007;Arango et al 2009;Moreno et al 2010). In contrast, our sample consisted mainly of children with autistic spectrum disorders treated with risperidone.…”

Section: Discussionsupporting

confidence: 93%

“…Similarly, in European studies, an elevated risk of weight gain, obesity, and metabolic side effects has been reported in pediatric patients with bipolar disorder and psychotic disorders using SGAs. (Schimmelmann et al 2007;Arango et al 2009;Moreno et al 2010) On the other hand, European data are missing regarding the risk of overweight in pediatric populations with a psychiatric diagnosis with and without use of SGAs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differences in Body Mass Index z-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics

Hoogd

Overbeek

Heerdink

et al. 2012

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

These data show robust and significant differences in sex- and age-adjusted body weight and weight status in young pediatric Caucasian samples with and without use of SGAs independent of Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) (American Psychiatric Association 2000 ) diagnosis and nonantipsychotic medications. Weight status and metabolic effects of SGAs require careful attention, especially in youth.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Differences in Body Mass Index z-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics

Hoogd

Overbeek

Heerdink

et al. 2012

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Although not directly comparable in terms of methodology or the diagnostic groups investigated, this study provided efficacy outcomes consistent with previously reported outcomes in open-label studies of adolescents (McConville et al 2000;Shaw et al 2001;Schimmelmann et al 2007) and controlled studies of adults with schizoprenia (Riedel et al 2007).…”

Section: Discussionsupporting

confidence: 80%

“…Evidence that quetiapine may also offer efficacy in adolescents with schizophrenia derives from three open-label studies, between 3-12 weeks' duration, that investigated quetiapine at doses up to 800 mg/day (McConville et al 2000;Shaw et al 2001;Schimmelmann et al 2007). McConville et al (2000) reported a 23-day study of 10 patients ages 12-16 years with a diagnosis of schizoaffective disorder or bipolar disorder with psychotic features.…”

Section: Introductionmentioning

confidence: 99%

“…Quetiapine at doses between 300 mg/day and 800 mg/day significantly reduced psychotic symptoms measured by rating scales including the Positive and Negative Syndrome Scale (PANSS) and the BPRS. Finally, Schimmelmann et al (2007) investigated quetiapine at doses between 200 mg/day and 800 mg/day for 12 weeks in 56 patients ages 12-17 years diagnosed with schizophrenia, schizophreniform, or schizoaffective disorders. Quetiapine was associated with significant improvements in PANSS total and positive scores, and demonstrated a safety profile in line with previous studies in this age group.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia Investigated in a 6-Week, Double-Blind, Placebo-Controlled Trial

Findling

McKenna

Earley³

et al. 2012

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents

Correll¹

2009

JAMA

897

745

View full text Add to dashboard Cite

ECOND-GENERATION ANTIPSYchotic medications are commonly and increasingly pres c r i b e d t o c h i l d r e n a n d adolescents in the United States as firstline treatment for psychotic disorders, bipolar disorder, and nonpsychotic mental disorders. 1 Increasingly, the cardiometabolic effects of secondgeneration antipsychotic medications have raised concern. 2 Cardiometabolic adverse effects, such as ageinappropriate weight gain, obesity, hypertension, and lipid and glucose abnormalities, are particularly problematic during development because they predict adult obesity, the metabolic syndrome, cardiovascular morbidity, and malignancy. [3][4][5][6] Emerging findings indicate that youth are especially vulnerable to antipsychotic medication−induced weight gain, 7-10 but limited prospective, pediatric data suggest minimal or no metabolic liabilities, except for olanzapine. 9,10 However, the interpretation of the data is hampered by variable prior antipsychotic medication exposure, which can obscure cardiometabolic effects. Therefore, data are needed in patients with minimal antipsychotic medication exposure. Such data are lacking in youth and are limited to small samples in adults. Furthermore, because isolated studies in chronic patients have implicated age 11 and anti-For editorial comment see p 1811. Context Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychotic medication. Objective To study the association of second-generation antipsychotic medications with body composition and metabolic parameters in patients without prior antipsychotic medication exposure. Design, Setting, and Patients Nonrandomized Second-Generation Antipsychotic Treatment Indications, Effectiveness and Tolerability in Youth (SATIETY) cohort study, conducted between December 2001 and September 2007 at semi-urban, tertiary care, academic inpatient and outpatient clinics in Queens, New York, with a catchment area of 4.5-million individuals. Of 505 youth aged 4 to 19 years with 1 week or less of antipsychotic medication exposure, 338 were enrolled (66.9%). Of these patients, 272 had at least 1 postbaseline assessment (80.5%), and 205 patients who completed the study (60.7%). Patients had mood spectrum (n=130; 47.8%), schizophrenia spectrum (n=82; 30.1%), and disruptive or aggressive behavior spectrum (n=60; 22.1%) disorders. Fifteen patients who refused participation or were nonadherent served as a comparison group. Intervention Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks. Main Outcome Measures Weight gain and changes in lipid and metabolic parameters.Results After a median of 10.8 weeks (interquartile range, 10.5-11.2 weeks) of treatment, weight increased by 8.5 kg (95% confidence interval [CI], 7.4 to 9.7 kg) with olanzapine (n=45), by 6.1 kg (95% CI, 4.9 to 7.2 kg) with quetiapine (n=36), by 5.3 kg (95% CI, 4.8 to 5.9 kg) with risperidone (n=135), and by 4.4 kg (95% CI, 3.7 to ...

show abstract

A Prospective 12-Week Study of Quetiapine in Adolescents with Schizophrenia Spectrum Disorders

Cited by 36 publications

References 29 publications

Differences in Body Mass Index z-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics

Differences in Body Mass Index z-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics

Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia Investigated in a 6-Week, Double-Blind, Placebo-Controlled Trial

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents

Contact Info

Product

Resources

About